Shanghai Manbo Biopharmaceutical Technology Co., Ltd. was established in February 2019. It is a wholly-owned subsidiary of MineBio Life Sciences Limited in Hong Kong, Macau, and Taiwan. With a deep focus on the fields of life sciences and biopharmaceuticals, the company leverages deep industry resources, over 400 domestic high-quality drug research and development customer groups, and cooperation advantages with international cutting-edge brands to connect the world's innovative biotechnology with China's local research and development needs.

Manbo Biotechnology adheres to the concept of "screening international quality products and empowering local research and development", strictly selects internationally innovative and peer-reviewed products and technologies, introduces solutions recognized by FDA and other institutions, carries out professional development, incubation and promotion in China, and helps domestic R&D workers to experience technological revolution and share the technological dividends brought by the progress of R&D tools.

The company's core business focuses on the research and development of biological products such as cell therapy/gene therapy/stem cells/regenerative medicine, enzyme/recombinant protein/antibody drugs, and preclinical drug development. We specialize in providing niche, cutting-edge, compliant, and efficient products and services, including:

1) We provide a full range of products ranging from research grade to cGMP clinical grade, including animal free culture media, transfection reagents, virus transduction enhancers, collagenase, etc., which can adapt to the seamless connection needs of ATMP (Advance Therapy Medicinal Products) drug development from basic research, clinical translation to later commercialization.

2) Provide high-throughput cell-free screening systems and flexible CHO engineered cell lines for protein, enzyme, and antibody drug development, along with corresponding application plans, effectively supporting the commercial production of related biological products, improving research and development efficiency and product stability.

3) We provide in vitro modeling solutions, including high-quality primary human liver cells and 3D high-throughput screening models, 3D gas-liquid interface lung model culture, microfluidic organ chips and other related products, which can meet the experimental needs of longer culture life and higher detection sensitivity, supporting translational medicine research, drug toxicity assessment and disease modeling scenarios.

Manbo Biotechnology not only provides high-quality product supply, but also has the ability to adapt technology and provide after-sales support, continuously providing various services for domestic research and development institutions and pharmaceutical companies. In the future, the company will deepen its core areas, integrate high-quality resources, and empower the development of the cell, gene therapy industry, bioproducts industry, regenerative medicine industry, and the entire life sciences industry!